MGAT2

Summary

MGAT2 (alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase, HGNC:7045) is a protein-coding gene on chromosome 14q21.3, encoding Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (Q10469). Plays an essential role in protein N-glycosylation.

The product of this gene is a Golgi enzyme catalyzing an essential step in the conversion of oligomannose to complex N-glycans. The enzyme has the typical glycosyltransferase domains: a short N-terminal cytoplasmic domain, a hydrophobic non-cleavable signal-anchor domain, and a C-terminal catalytic domain. Mutations in this gene may lead to carbohydrate-deficient glycoprotein syndrome, type II. The coding region of this gene is intronless. Transcript variants with a spliced 5’ UTR may exist, but their biological validity has not been determined.

Source: NCBI Gene 4247 — RefSeq curated summary.

At a glance

• Gene–disease (curated): MGAT2-congenital disorder of glycosylation (Definitive, GenCC)
• Clinical variants (ClinVar): 166 total — 6 pathogenic, 6 likely-pathogenic
• Phenotypes (HPO): 99
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_002408

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7045
Approved symbol	MGAT2
Name	alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase
Location	14q21.3
Locus type	gene with protein product
Status	Approved
Aliases	GNT-II
Ensembl gene	ENSG00000168282
Ensembl biotype	protein_coding
OMIM	602616
Entrez	4247

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000305386

RefSeq mRNA: 1 — MANE Select: NM_002408 NM_002408

CCDS: CCDS9690

Canonical transcript exons

ENST00000305386 — 1 exons

Exon	Start	End
ENSE00001175172	49620799	49623481

Expression profiles

Bgee: expression breadth ubiquitous, 278 present calls, max score 96.44.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 21.2176 / max 125.4906, expressed in 1814 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
139438	20.7873	1813
139437	0.4304	209

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
jejunal mucosa	UBERON:0000399	96.44	gold quality
mucosa of sigmoid colon	UBERON:0004993	94.96	gold quality
colonic mucosa	UBERON:0000317	94.64	gold quality
decidua	UBERON:0002450	93.90	gold quality
periodontal ligament	UBERON:0008266	92.87	gold quality
corpus epididymis	UBERON:0004359	92.10	gold quality
caput epididymis	UBERON:0004358	91.94	gold quality
bronchial epithelial cell	CL:0002328	91.74	gold quality
cauda epididymis	UBERON:0004360	91.66	gold quality
seminal vesicle	UBERON:0000998	91.08	gold quality
adult organism	UBERON:0007023	90.70	gold quality
skin of hip	UBERON:0001554	90.60	gold quality
epithelium of bronchus	UBERON:0002031	90.07	gold quality
superficial temporal artery	UBERON:0001614	90.05	gold quality
choroid plexus epithelium	UBERON:0003911	89.90	gold quality
pericardium	UBERON:0002407	89.80	gold quality
bronchus	UBERON:0002185	89.75	gold quality
granulocyte	CL:0000094	89.71	gold quality
duodenum	UBERON:0002114	89.32	gold quality
monocyte	CL:0000576	89.25	gold quality
mononuclear cell	CL:0000842	89.13	gold quality
parotid gland	UBERON:0001831	89.11	gold quality
leukocyte	CL:0000738	89.10	gold quality
cartilage tissue	UBERON:0002418	88.80	gold quality
bone marrow cell	CL:0002092	88.53	gold quality
pigmented layer of retina	UBERON:0001782	88.43	gold quality
retina	UBERON:0000966	88.40	gold quality
oral cavity	UBERON:0000167	88.25	gold quality
mammary duct	UBERON:0001765	88.22	gold quality
heart right ventricle	UBERON:0002080	88.00	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.67

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NR1I2

miRNA regulators (miRDB)

89 targeting MGAT2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-5692A	100.00	74.40	6850
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-5688	99.96	73.23	4504

Literature-anchored findings (GeneRIF, showing 5)

• Golgi N-glycosyltransferases beta-1,2-N-acetylglucosaminyltransferase I, beta-1,2-N-acetylglucosaminyltransferase II, 1,4-galactosyltransferase I, and alpha-2,6-sialyltransferase I form both homo- and heterodimeric enzyme complexes in live cells (PMID:20378551)
• UDP-galactose (SLC35A2) and UDP-N-acetylglucosamine (SLC35A3) Transporters Form Glycosylation-related Complexes with Mannoside Acetylglucosaminyltransferases (Mgats). (PMID:25944901)
• The recombinant hGnTII was purified from silkworm larval hemolymph in two steps by using tandem affinity purification tags, with a yield of approximately 120 mug from 10 mL hemolymph, and exhibited glycosyltransferase activity and strict substrate specificity. The enzyme was found to be N-glycosylated by the enzymatic cleavage of glycans, while hGnTII expressed in insect cells had not been reported to be glycosylated. (PMID:29409697)
• These data suggest that substrate binding by MGAT2 employs both conserved and convergent catalytic subsite modules to provide substrate selectivity and catalysis. More broadly, the MGAT2 active-site architecture demonstrates how glycosyltransferases create complementary modular templates for regiospecific extension of glycan structures in mammalian cells. (PMID:29666272)
• Immune dysfunction in MGAT2-CDG: A clinical report and review of the literature. (PMID:33044030)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	mgat2	ENSDARG00000052408
mus_musculus	Mgat2	ENSMUSG00000043998
rattus_norvegicus	Mgat2	ENSRNOG00000004234
drosophila_melanogaster	Mgat2	FBGN0039738
caenorhabditis_elegans		WBGENE00001645

Protein

Protein identifiers

Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase — Q10469 (reviewed: Q10469)

Alternative names: Beta-1,2-N-acetylglucosaminyltransferase II, GlcNAc-T II, Mannoside acetylglucosaminyltransferase 2, N-glycosyl-oligosaccharide-glycoprotein N-acetylglucosaminyltransferase II

All UniProt accessions (1): Q10469

UniProt curated annotations — full annotation on UniProt →

Function. Plays an essential role in protein N-glycosylation. Catalyzes the transfer of N-acetylglucosamine (GlcNAc) onto the free terminal mannose moiety in the core structure of the nascent N-linked glycan chain, giving rise to the second branch in complex glycans.

Subunit / interactions. Homodimer.

Subcellular location. Golgi apparatus membrane.

Disease relevance. Congenital disorder of glycosylation 2A (CDG2A) [MIM:212066] A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. The disease is caused by variants affecting the gene represented in this entry.

Pathway. Protein modification; protein glycosylation.

Similarity. Belongs to the glycosyltransferase 16 (GT16) protein family.

RefSeq proteins (1): NP_002399* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007754	GlcNAc_II	Family
IPR029044	Nucleotide-diphossugar_trans	Homologous_superfamily

Pfam: PF05060

Enzyme classification (BRENDA):

• EC 2.4.1.143 — alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (BRENDA: 19 organisms, 41 substrates, 17 inhibitors, 35 Km, 16 kcat entries)

Substrate kinetics (BRENDA)

17 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
BETA-D-GLCNAC-(1->2)-ALPHA-D-MAN-(1->3)-[ALPHA-D	0.062–0.557	8
UDP-ALPHA-D-GLCNAC	0.295–4.3	8
ALPHA-D-MANNOSYL-1,6-(N-ACETYL-D-GLUCOSAMINYL-1,	0.0166–0.19	3
UDP-N-ACETYLGLUCOSAMINE	0.018–0.96	3
3-DEOXY-MANALPHA(1-6)(GLCNACBETA(1-2)MANALPHA(1-	3.7	1
3-O-METHYL-MANALPHA(1-6)(GLCNACBETA(1-2)MANALPHA	0.26	1
4-DEOXY-MANALPHA(1-6)(GLCNACBETA(1-2)MANALPHA(1-	0.22	1
4-O-METHYL-ALPHA-D-MANNOSYL-1,6-(N-ACETYL-BETA-D	0.16	1
4-O-METHYL-MANALPHA(1-6)(GLCNACBETA(1-2)MANALPHA	0.26	1
6-DEOXY-MANALPHA(1-6)(GLCNACBETA(1-2)MANALPHA(1-	0.25	1
6-O-METHYL-MANALPHA(1-6)(GLCNACBETA(1-2)MANALPHA	0.2	1
ALPHA-D-MANNOSYL-1,6-(N-ACETYL-BETA-D-GLUCOSAMIN	0.55	1
ALPHA-D-MANNOSYL-1,6-(N-ACETYL-BETA-D-GLUCOSAMIN	0.13	1
MANALPHA(1-6)(GLCNACBETA(1-2)-6-DEOXY-MANALPHA(1	0.55	1
MANALPHA(1-6)(GLCNACBETA(1-2)4-O-METHYL-MANALPHA	0.16	1

Catalyzed reactions (Rhea), 1 shown:

• an N(4)-{beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc}-L-asparaginyl-[protein] + UDP-N-acetyl-alpha-D-glucosamine = N(4)-{beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc}-L-asparaginyl-[protein] + UDP + H(+) (RHEA:12941)

UniProt features (63 total): helix 15, strand 14, mutagenesis site 8, binding site 6, disulfide bond 5, turn 5, sequence variant 3, topological domain 2, glycosylation site 2, chain 1, transmembrane region 1, sequence conflict 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
5VCM	X-RAY DIFFRACTION	1.6
5VCR	X-RAY DIFFRACTION	1.99
5VCS	X-RAY DIFFRACTION	2.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q10469-F1	86.01	0.75

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (6): 123–127; 154; 229–233; 261; 298; 374

Disulfide bonds (5): 196–210, 283–286, 334–357, 339–440, 378–386

Glycosylation sites (2): 69, 86

Mutagenesis-validated functional residues (8):

Position	Phenotype
198	strongly decreased catalytic activity and affinity for udp-glcnac.
217	nearly abolishes catalytic activity.
259	loss of catalytic activity.
294	strongly decreased catalytic activity and affinity for udp-glcnac.
318	strongly decreased catalytic activity and affinity for udp-glcnac.
344	nearly abolishes catalytic activity and strongly decreases affinity for udp-glcnac.
346	loss of catalytic activity.
347	loss of catalytic activity.

Function

Pathways and Gene Ontology

Reactome pathways

18 pathways

ID	Pathway
R-HSA-4793952	Defective MGAT2 causes CDG-2a
R-HSA-9694548	Maturation of spike protein
R-HSA-975578	Reactions specific to the complex N-glycan synthesis pathway
R-HSA-1643685	Disease
R-HSA-3781860	Diseases associated with N-glycosylation of proteins
R-HSA-3781865	Diseases of glycosylation
R-HSA-392499	Metabolism of proteins
R-HSA-446203	Asparagine N-linked glycosylation
R-HSA-5663205	Infectious disease
R-HSA-5668914	Diseases of metabolism
R-HSA-597592	Post-translational protein modification
R-HSA-948021	Transport to the Golgi and subsequent modification
R-HSA-9679506	SARS-CoV Infections
R-HSA-9694516	SARS-CoV-2 Infection
R-HSA-9694635	Translation of Structural Proteins
R-HSA-975576	N-glycan antennae elongation in the medial/trans-Golgi
R-HSA-9772573	Late SARS-CoV-2 Infection Events
R-HSA-9824446	Viral Infection Pathways

MSigDB gene sets: 469 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_UP, GSE45365_NK_CELL_VS_CD8A_DC_UP, RNGTGGGC_UNKNOWN, GOBP_OLIGOSACCHARIDE_METABOLIC_PROCESS, GOBP_PROTEIN_N_LINKED_GLYCOSYLATION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, KEGG_N_GLYCAN_BIOSYNTHESIS, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, MARTINEZ_RB1_TARGETS_UP, ONKEN_UVEAL_MELANOMA_UP, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS, FISCHER_G2_M_CELL_CYCLE, GROSS_HYPOXIA_VIA_ELK3_UP, GROSS_HYPOXIA_VIA_HIF1A_UP, GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_DN

GO Biological Process (5): protein N-linked glycosylation (GO:0006487), oligosaccharide biosynthetic process (GO:0009312), obsolete protein N-linked glycosylation via asparagine (GO:0018279), viral protein processing (GO:0019082), obsolete protein glycosylation (GO:0006486)

GO Molecular Function (6): alpha-1,6-mannosylglycoprotein 2-beta-N-acetylglucosaminyltransferase activity (GO:0008455), manganese ion binding (GO:0030145), protein homodimerization activity (GO:0042803), transferase activity (GO:0016740), glycosyltransferase activity (GO:0016757), metal ion binding (GO:0046872)

GO Cellular Component (4): Golgi membrane (GO:0000139), Golgi apparatus (GO:0005794), Golgi stack (GO:0005795), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-15 pathways:

Category	Pathways
Disease	2
Diseases associated with N-glycosylation of proteins	1
Translation of Structural Proteins	1
N-glycan antennae elongation in the medial/trans-Golgi	1
Diseases of glycosylation	1
Diseases of metabolism	1
Post-translational protein modification	1
Metabolism of proteins	1
Asparagine N-linked glycosylation	1
Viral Infection Pathways	1
SARS-CoV Infections	1
Late SARS-CoV-2 Infection Events	1
Transport to the Golgi and subsequent modification	1
SARS-CoV-2 Infection	1
Infectious disease	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
glycoprotein biosynthetic process	1
oligosaccharide metabolic process	1
carbohydrate biosynthetic process	1
viral process	1
viral gene expression	1
acetylglucosaminyltransferase activity	1
catalytic activity, acting on a glycoprotein	1
transition metal ion binding	1
identical protein binding	1
protein dimerization activity	1
catalytic activity	1
transferase activity	1
cation binding	1
Golgi apparatus	1
bounding membrane of organelle	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
Golgi apparatus subcompartment	1
cellular anatomical structure	1

Protein interactions and networks

STRING

550 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MGAT2	MGAT1	P26572	943
MGAT2	MAN2A1	Q16706	790
MGAT2	MGAT5	Q09328	785
MGAT2	MAN2A2	P49641	726
MGAT2	MGAT3	Q09327	716
MGAT2	MGAT4A	Q9UM21	692
MGAT2	MGAT4B	Q9UQ53	692
MGAT2	FUT8	Q9BYC5	677
MGAT2	POMGNT1	Q8WZA1	654
MGAT2	GUSB	P08236	647
MGAT2	GCNT2	Q8N0V5	646
MGAT2	ALG3	Q92685	625
MGAT2	EXTL3	O43909	564
MGAT2	ST3GAL3	Q11203	558
MGAT2	MGAT5B	Q3V5L5	549

IntAct

39 interactions, top by confidence:

A	B	Type	Score
TOR1AIP2	TMEM223	psi-mi:“MI:0914”(association)	0.530
PEX19	FAM20B	psi-mi:“MI:0914”(association)	0.530
PEX19	MYO1D	psi-mi:“MI:0914”(association)	0.530
HSCB	RBP5	psi-mi:“MI:0914”(association)	0.350
ATAD3A	TMEM223	psi-mi:“MI:0914”(association)	0.350
P		psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
	PLOD2	psi-mi:“MI:0914”(association)	0.350
SHANK3	IGKV3D-15	psi-mi:“MI:0914”(association)	0.350
PDGFRA	GXYLT2	psi-mi:“MI:0914”(association)	0.350
TCTN2	TMEM131L	psi-mi:“MI:0914”(association)	0.350
ST14	LIPT2	psi-mi:“MI:0914”(association)	0.350
SCGB2A2	RTL8C	psi-mi:“MI:0914”(association)	0.350
BCAP31	GOLIM4	psi-mi:“MI:0914”(association)	0.350
CPQ	COX7A2L	psi-mi:“MI:0914”(association)	0.350
TMPRSS13	TOR1A	psi-mi:“MI:0914”(association)	0.350
MAN1A1	GPC4	psi-mi:“MI:0914”(association)	0.350
MINPP1	MGAT2	psi-mi:“MI:0914”(association)	0.350
REEP5	ESYT2	psi-mi:“MI:0914”(association)	0.350
TSPAN8	POTEF	psi-mi:“MI:0914”(association)	0.350
MAN1A1	PLOD2	psi-mi:“MI:0914”(association)	0.350
PEX19	KCNN4	psi-mi:“MI:0914”(association)	0.350
TOR1AIP2	XPO1	psi-mi:“MI:0914”(association)	0.350
SAAL1	TMEM223	psi-mi:“MI:0914”(association)	0.350
SLC30A1	PSMD11	psi-mi:“MI:0914”(association)	0.350
SLC30A10	GOLIM4	psi-mi:“MI:0914”(association)	0.350
SLC30A7	ESYT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (58): MGAT2 (Affinity Capture-MS), MGAT2 (Affinity Capture-MS), MGAT2 (Affinity Capture-MS), MGAT2 (Affinity Capture-MS), MGAT2 (Affinity Capture-MS), MGAT2 (Affinity Capture-MS), S (Reconstituted Complex), MGAT2 (Proximity Label-MS), MGAT2 (Affinity Capture-MS), MGAT2 (Negative Genetic), MGAT2 (Affinity Capture-MS), MGAT2 (Affinity Capture-MS), MGAT2 (Affinity Capture-MS), MGAT2 (Affinity Capture-MS), MGAT2 (Affinity Capture-MS)

ESM2 similar proteins: A0A4Z3, A1Y9I9, A4FUH1, B6CZ46, B6CZ56, B6CZ62, D3ZNQ3, G3V9Q9, O43505, O60512, O60909, O94766, P14616, P14617, P58158, Q09326, Q10469, Q2NKH9, Q2YDM8, Q3V1N9, Q3V5L5, Q4R5T7, Q5EA01, Q5EB73, Q5JU69, Q5M936, Q5NVN3, Q5R4S2, Q5R868, Q5YB40, Q5ZLK4, Q64716, Q6AYR4, Q765H6, Q7Z4J2, Q8BGT9, Q8BWP8, Q8IXK2, Q8NCL4, Q8R1J9

Diamond homologs: O19071, Q09326, Q10469, Q921V5, Q9FT88

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 52 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Metal ion SLC transporters	6	109.3×	2e-09
R-HSA-425366	5	27.5×	5e-05
SLC-mediated transmembrane transport	5	9.0×	8e-03

GO biological processes:

GO term	Partners	Fold	FDR
zinc ion transmembrane transport	8	122.1×	3e-13
intracellular zinc ion homeostasis	7	73.3×	7e-10

Disease & clinical

Clinical variants and AI predictions

ClinVar

166 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	6
Likely pathogenic	6
Uncertain significance	120
Likely benign	19
Benign	6

Top pathogenic / likely-pathogenic (12)

Variant ID	HGVS	Classification
617657	NM_002408.4(MGAT2):c.753dup (p.Ala252fs)	Pathogenic
617658	NM_002408.4(MGAT2):c.91C>T (p.Gln31Ter)	Pathogenic
617661	NM_002408.4(MGAT2):c.799G>C (p.Asp267His)	Pathogenic
6990	NM_002408.4(MGAT2):c.785A>G (p.His262Arg)	Pathogenic
6991	NM_002408.4(MGAT2):c.952A>G (p.Asn318Asp)	Pathogenic
6992	NM_002408.4(MGAT2):c.1017T>A (p.Cys339Ter)	Pathogenic
30270	NM_002408.4(MGAT2):c.711G>C (p.Lys237Asn)	Likely pathogenic
3061920	NM_002408.4(MGAT2):c.1085G>A (p.Trp362Ter)	Likely pathogenic
3065025	NM_002408.4(MGAT2):c.1199_1202del (p.Asn400fs)	Likely pathogenic
489288	NM_002408.4(MGAT2):c.745C>T (p.Arg249Ter)	Likely pathogenic
596219	NM_002408.4(MGAT2):c.1006_1009del (p.Asp336fs)	Likely pathogenic
817419	NM_002408.4(MGAT2):c.346dup (p.Arg116fs)	Likely pathogenic

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

2939 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:49621722:A:C	S152R	1.000
14:49621724:C:A	S152R	1.000
14:49621724:C:G	S152R	1.000
14:49621830:T:C	F188L	1.000
14:49621831:T:G	F188C	1.000
14:49621832:T:A	F188L	1.000
14:49621832:T:G	F188L	1.000
14:49621896:T:A	C210S	1.000
14:49621897:G:C	C210S	1.000
14:49621936:G:C	R223T	1.000
14:49621936:G:T	R223I	1.000
14:49621937:A:C	R223S	1.000
14:49621937:A:T	R223S	1.000
14:49621961:A:C	K231N	1.000
14:49621961:A:T	K231N	1.000
14:49622303:C:A	N345K	1.000
14:49622303:C:G	N345K	1.000
14:49622306:G:C	W346C	1.000
14:49622306:G:T	W346C	1.000
14:49622308:A:C	D347A	1.000
14:49622308:A:T	D347V	1.000
14:49622554:G:A	G429E	1.000
14:49622559:T:A	W431R	1.000
14:49622559:T:C	W431R	1.000
14:49622561:G:C	W431C	1.000
14:49622561:G:T	W431C	1.000
14:49622572:G:C	R435T	1.000
14:49622572:G:T	R435M	1.000
14:49621565:C:A	N99K	0.999
14:49621565:C:G	N99K	0.999

dbSNP variants (sampled 300 via entrez): RS1000194527 (14:49619782 T>C), RS1000458463 (14:49621556 C>T), RS1000796282 (14:49620645 G>A), RS1000864356 (14:49619362 G>A), RS1000981677 (14:49619604 T>G), RS1001322400 (14:49619685 C>G), RS1002967671 (14:49620548 C>A), RS1003201135 (14:49619697 T>C), RS1003340772 (14:49620385 G>A,C), RS1003647744 (14:49620606 T>C), RS1003705196 (14:49619467 G>C), RS1003833972 (14:49619163 A>G), RS1003910403 (14:49619438 C>A,T), RS1005048070 (14:49618961 A>G,T), RS1005716041 (14:49620833 G>A)

Disease associations

OMIM: gene MIM:602616 | disease phenotypes: MIM:212066

GenCC curated gene-disease

Disease	Classification	Inheritance
MGAT2-congenital disorder of glycosylation	Definitive	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
MGAT2-congenital disorder of glycosylation	Moderate	AR

Mondo (1): MGAT2-congenital disorder of glycosylation (MONDO:0008908)

Orphanet (1): MGAT2-CDG (Orphanet:79329)

HPO phenotypes

99 total (30 of 99 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000154	Wide mouth
HP:0000194	Open mouth
HP:0000212	Gingival overgrowth
HP:0000232	Everted lower lip vermilion
HP:0000233	Thin vermilion border
HP:0000248	Brachycephaly
HP:0000252	Microcephaly
HP:0000253	Progressive microcephaly
HP:0000256	Macrocephaly
HP:0000268	Dolichocephaly
HP:0000278	Retrognathia
HP:0000303	Mandibular prognathia
HP:0000316	Hypertelorism
HP:0000343	Long philtrum
HP:0000358	Posteriorly rotated ears
HP:0000363	Abnormal earlobe morphology
HP:0000369	Low-set ears
HP:0000395	Prominent antihelix
HP:0000400	Macrotia
HP:0000407	Sensorineural hearing impairment
HP:0000426	Prominent nasal bridge
HP:0000444	Convex nasal ridge
HP:0000470	Short neck
HP:0000494	Downslanted palpebral fissures
HP:0000527	Long eyelashes
HP:0000574	Thick eyebrow
HP:0000678	Dental crowding
HP:0000699	Diastema
HP:0000718	Aggressive behavior

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C535752	Congenital disorder of glycosylation type 2A (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2321630 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 35 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL3912712	BMS-963272	1	25
CHEMBL5418882	BMS-986172	1	10

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

593 measured of 596 human assays (596 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
(2S)-2-[2-chloro-4-(4,4,4-trifluorobutoxy)phenyl]-4-(5-cyclopropylthiophen-2-yl)-5-(2H-tetrazol-5-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	IC50	0.2 nM	US-9701672: Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders
(2S)-4-(5-ethyl-1,3-thiazol-2-yl)-2-[2-fluoro-4-(6,6,6-trifluorohexoxy)phenyl]-5-(2H-tetrazol-5-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	IC50	0.5 nM	US-9701672: Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders
N-[[(2S)-4-[5-(difluoromethoxy)-2-pyridinyl]-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-5-yl]methyl]-2-methylsulfonylacetamide	IC50	0.62 nM	US-10335401: Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity
(2S)-2-[2-chloro-4-(6,6,6-trifluorohexoxy)phenyl]-4-(5-cyclopropyl-1,3-thiazol-2-yl)-5-(2H-tetrazol-5-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	IC50	0.7 nM	US-9701672: Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders
N-[[(2S)-4-[5-(2-hydroxypropan-2-yl)-2-pyridinyl]-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-5-yl]methyl]-2-methylsulfonylacetamide	IC50	0.73 nM	US-10335401: Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity
4-(4-methylphenyl)-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-N-[4-(trifluoromethoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridine-5-carboxamide	IC50	1 nM	US-9187424: Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
4-(4-methylphenyl)-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-N-[4-(trifluoromethyl)phenyl]-1,3-dihydropyridine-5-carboxamide	IC50	1 nM	US-9187424: Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
N-(4-hydroxyphenyl)-4-(4-methylphenyl)-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridine-5-carboxamide	IC50	1 nM	US-9187424: Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
4-(4-methylphenyl)-N-(1,2-oxazol-5-yl)-6-oxo-2-(trifluoromethyl)-2-[4-(3,3,3-trifluoropropoxy)phenyl]-1,3-dihydropyridine-5-carboxamide	IC50	1 nM	US-9187424: Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
4-[4-(difluoromethoxy)phenyl]-2-[2-fluoro-4-(6,6,6-trifluorohexoxy)phenyl]-5-(2H-tetrazol-5-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	IC50	1 nM	US-9187424: Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
2-[3-fluoro-4-(6,6,6-trifluorohexoxy)phenyl]-4-naphthalen-2-yl-5-(2H-tetrazol-5-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	IC50	1 nM	US-9187424: Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
(2S)-4-[4-(difluoromethyl)phenyl]-2-[2-fluoro-4-(6,6,6-trifluorohexoxy)phenyl]-N-methylsulfonyl-6-oxo-2-(trifluoromethyl)-1,3-dihydropyridine-5-carboxamide	IC50	1 nM	US-9822074: Dihydropyridinone MGAT2 inhibitors
(2S)-4-(4-cyclopropylphenyl)-2-[2-fluoro-4-(6,6,6-trifluorohexoxy)phenyl]-N-methylsulfonyl-6-oxo-2-(trifluoromethyl)-1,3-dihydropyridine-5-carboxamide	IC50	1 nM	US-9822074: Dihydropyridinone MGAT2 inhibitors
2-methylsulfonyl-N-[[(2S)-6-oxo-4-(5-prop-1-en-2-yl-2-pyridinyl)-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-5-yl]methyl]acetamide	IC50	1 nM	US-10335401: Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity
(S,E)-2-Methyl-N-(2,2,2-trifluoro-1-(4-((5,5,5-trifluoropentyl)oxy phenyl)ethylidene)propane-2-sulfinamide	IC50	1.1 nM	US-9701672: Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders
(2S)-2-[2-chloro-4-(4,4,4-trifluorobutoxy)phenyl]-4-(5-cyclopropyl-1,3-thiazol-2-yl)-5-(2H-tetrazol-5-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	IC50	1.1 nM	US-9701672: Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders
N-[[(2S)-4-[5-(difluoromethyl)-2-pyridinyl]-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-5-yl]methyl]-2-methylsulfonylacetamide	IC50	1.1 nM	US-10335401: Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity
1-(5-Cyclopropylthiazol-2-yl)ethanone	IC50	1.2 nM	US-9701672: Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders
(2S)-4-(5-cyclopropylthiophen-2-yl)-2-[2-methoxy-4-(4,4,4-trifluorobutoxy)phenyl]-5-(2H-tetrazol-5-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	IC50	1.4 nM	US-9701672: Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders
(2S)-4-(5-cyclopropyl-1,3-thiazol-2-yl)-2-[2-fluoro-4-(4,4,4-trifluorobutoxy)phenyl]-5-(2H-tetrazol-5-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	IC50	1.4 nM	US-9701672: Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders
1-(5-Methylthiazol-2-yl)ethanone	IC50	1.5 nM	US-9701672: Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders
(S)—N-(4-(5-Ethylthiophen-2-yl)-2-oxo-6-(4-((6,6,6-trifluorohexyl)oxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridin-3-yl)-2-(methylsulfonyl)acetamide	IC50	1.5 nM	US-9701672: Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders
2-[(1R)-1-(3,5-difluorophenyl)ethyl]-N-[3-(pyrrolidine-1-carbonyl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-1H-isoquinoline-7-sulfonamide	IC50	1.6 nM	US-10065945: Isoquinoline derivatives as MGAT2 inhibitors
N-[[(2S)-4-[5-(difluoromethyl)-2-pyridinyl]-6-oxo-2-(trifluoromethyl)-2-[4-(3,3,3-trifluoropropyl)phenyl]-1,3-dihydropyridin-5-yl]methyl]-2-methylsulfonylacetamide	IC50	1.9 nM	US-10335401: Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity
4-(2-fluoro-4-methoxyphenyl)-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridine-5-carbonitrile	IC50	2 nM	US-9187424: Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
N-[4-[4-(difluoromethoxy)phenyl]-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-5-yl]-1,2-oxazole-5-carboxamide	IC50	2 nM	US-9187424: Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
3-bromo-N-[4-(4-methylphenyl)-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-5-yl]-1,2-oxazole-5-carboxamide	IC50	2 nM	US-9187424: Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
4-(5,6,7,8-tetrahydronaphthalen-2-yl)-5-(tetrazolidin-5-yl)-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	IC50	2 nM	US-9187424: Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
N-[4-[4-(difluoromethoxy)phenyl]-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-5-yl]pyridine-4-carboxamide	IC50	2 nM	US-9187424: Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
2-[2-fluoro-4-(6,6,6-trifluorohexoxy)phenyl]-4-naphthalen-2-yl-5-(2H-tetrazol-5-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	IC50	2 nM	US-9187424: Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
4-[4-(cyclopropylmethyl)phenyl]-2-[2-fluoro-4-(4,4,4-trifluorobutoxy)phenyl]-5-(2H-tetrazol-5-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	IC50	2 nM	US-9187424: Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
2-[2-fluoro-4-(5,5,5-trifluoropentoxy)phenyl]-4-(4-methylphenyl)-5-(2H-tetrazol-5-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	IC50	2 nM	US-9187424: Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
N-[4-(4-methylphenyl)-6-oxo-2-(4-phenylmethoxyphenyl)-2-(trifluoromethyl)-1,3-dihydropyridin-5-yl]-2-methylsulfonylacetamide	IC50	2 nM	US-9187424: Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
4-[4-(difluoromethoxy)phenyl]-6-oxo-N-pyridin-3-yl-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridine-5-carboxamide	IC50	2 nM	US-9187424: Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
4-(2-fluoro-4-methylphenyl)-N-(4-methoxyphenyl)-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridine-5-carboxamide	IC50	2 nM	US-9187424: Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
2-(methanesulfonamido)-N-[4-(4-methylphenyl)-2-oct-1-ynyl-6-oxo-2-(trifluoromethyl)-1,3-dihydropyridin-5-yl]acetamide	IC50	2 nM	US-9187424: Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
(2R)-N-cyclopropylsulfonyl-2-(5-heptyl-1,3-thiazol-2-yl)-4-(4-methylphenyl)-6-oxo-2-(trifluoromethyl)-1,3-dihydropyridine-5-carboxamide	IC50	2 nM	US-9822074: Dihydropyridinone MGAT2 inhibitors
(2S)-N-cyclopropylsulfonyl-4-(5-cyclopropyl-1,3-thiazol-2-yl)-2-[2-fluoro-4-(4,4,4-trifluorobutoxy)phenyl]-6-oxo-2-(trifluoromethyl)-1,3-dihydropyridine-5-carboxamide	IC50	2 nM	US-9822074: Dihydropyridinone MGAT2 inhibitors
(2S)-4-[1-(cyclopropylmethyl)pyrazol-3-yl]-N-cyclopropylsulfonyl-6-oxo-2-(trifluoromethyl)-2-[4-(5,5,5-trifluoropentyl)phenyl]-1,3-dihydropyridine-5-carboxamide	IC50	2 nM	US-9822074: Dihydropyridinone MGAT2 inhibitors
(2S)-N-cyclopropylsulfonyl-4-(4-ethylphenyl)-2-methyl-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-1,3-dihydropyridine-5-carboxamide	IC50	2 nM	US-9822074: Dihydropyridinone MGAT2 inhibitors
(2S)-4-(5-cyclopropyl-1H-imidazol-2-yl)-2-[2-fluoro-4-(4,4,4-trifluorobutoxy)phenyl]-5-(5-oxotetrazolidin-1-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	IC50	2 nM	US-10093650: Tetrazolone-substituted dihydropyridinone MGAT2 inhibitors
1-(5-Ethylthiazol-2-yl)ethanone	IC50	2.1 nM	US-9701672: Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders
(2S)-4-(5-ethyl-1,3-thiazol-2-yl)-2-[2-fluoro-4-(4,4,4-trifluorobutoxy)phenyl]-5-(2H-tetrazol-5-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	IC50	2.1 nM	US-9701672: Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders
1-(5-Cyclopropylthiophen-2-yl)ethanone	IC50	2.2 nM	US-9701672: Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders
(2S)-4-(5-ethylthiophen-2-yl)-5-(2H-tetrazol-5-yl)-2-[4-(6,6,6-trifluorohexoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	IC50	2.2 nM	US-9701672: Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders
N-[[(2S)-4-(5-methyl-2-pyridinyl)-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-5-yl]methyl]-1,2-oxazole-5-carboxamide	IC50	2.2 nM	US-10335401: Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity
3,3,3-trifluoro-N-[[(2S)-4-(5-methyl-2-pyridinyl)-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-5-yl]methyl]propanamide	IC50	2.3 nM	US-10335401: Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity
(S,E)-2-Methyl-N-(2,2,2-trifluoro-1-(4-(4,4,4-trifluorobutoxy) phenyl)ethylidene)propane-2-sulfinamide	IC50	2.5 nM	US-9701672: Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders
N-[[(2S)-4-(5-methoxy-2-pyridinyl)-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-5-yl]methyl]-2-methylsulfonylacetamide	IC50	2.5 nM	US-10335401: Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity
(2S)-4-[1-(cyclopropylmethyl)pyrazol-3-yl]-5-(2H-tetrazol-5-yl)-2-[4-(6,6,6-trifluorohexoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	IC50	2.7 nM	US-9701672: Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders

ChEMBL bioactivities

1574 potent at pChembl≥5 of 1584 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.70	IC50	0.2	nM	CHEMBL4457459
9.70	IC50	0.2	nM	CHEMBL5824866
9.65	IC50	0.224	nM	CHEMBL5748063
9.54	IC50	0.285	nM	CHEMBL5768466
9.52	IC50	0.3	nM	CHEMBL4564881
9.42	IC50	0.38	nM	CHEMBL4572662
9.39	IC50	0.409	nM	CHEMBL6035455
9.36	IC50	0.439	nM	CHEMBL5816249
9.30	IC50	0.5	nM	CHEMBL5813899
9.21	IC50	0.62	nM	CHEMBL5991713
9.20	IC50	0.63	nM	CHEMBL3893594
9.19	IC50	0.64	nM	CHEMBL4463750
9.15	IC50	0.7	nM	CHEMBL5820966
9.15	IC50	0.706	nM	CHEMBL5871193
9.14	IC50	0.73	nM	CHEMBL4560153
9.12	IC50	0.76	nM	CHEMBL4457459
9.05	IC50	0.9	nM	CHEMBL4457459
9.00	IC50	1	nM	CHEMBL3581716
9.00	IC50	1	nM	CHEMBL3961967
9.00	IC50	1	nM	CHEMBL3965215
9.00	IC50	1	nM	CHEMBL3981198
9.00	IC50	1	nM	CHEMBL3937187
9.00	IC50	1	nM	CHEMBL3943858
9.00	IC50	1	nM	CHEMBL3932509
9.00	IC50	1	nM	CHEMBL3986069
9.00	IC50	1	nM	CHEMBL3960802
9.00	IC50	1	nM	CHEMBL6048166
9.00	IC50	1	nM	CHEMBL5960634
9.00	IC50	1	nM	CHEMBL5986274
9.00	IC50	1	nM	CHEMBL5779894
9.00	IC50	1	nM	CHEMBL5965136
9.00	IC50	1	nM	CHEMBL6046535
8.98	IC50	1.05	nM	CHEMBL5883234
8.98	IC50	1.04	nM	CHEMBL6036045
8.97	IC50	1.06	nM	CHEMBL5840224
8.96	IC50	1.1	nM	CHEMBL4465236
8.96	IC50	1.1	nM	CHEMBL4457459
8.96	IC50	1.1	nM	CHEMBL5934884
8.96	IC50	1.1	nM	CHEMBL5803244
8.95	IC50	1.12	nM	CHEMBL5998821
8.94	IC50	1.14	nM	CHEMBL5757628
8.94	IC50	1.15	nM	CHEMBL5890961
8.93	IC50	1.17	nM	CHEMBL6004478
8.92	IC50	1.2	nM	CHEMBL3581717
8.92	IC50	1.2	nM	CHEMBL5817097
8.92	IC50	1.2	nM	CHEMBL6016017
8.92	IC50	1.2	nM	CHEMBL5753020
8.92	IC50	1.21	nM	CHEMBL5755241
8.91	IC50	1.24	nM	CHEMBL5985571
8.90	IC50	1.25	nM	CHEMBL5838599

PubChem BioAssay actives

153 with measured affinity, of 183 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2S)-4-(5-cyclopropylthiophen-2-yl)-2-[2-fluoro-4-(4,4,4-trifluorobutoxy)phenyl]-5-(2H-tetrazol-5-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	1573551: Inhibition of recombinant human MGAT2	ic50	0.0002	uM
4-(5-ethylthiophen-2-yl)-3-(2H-tetrazol-5-yl)-6-[4-(6,6,6-trifluorohexoxy)-2-(trifluoromethyl)phenyl]-1H-pyridin-2-one	1573551: Inhibition of recombinant human MGAT2	ic50	0.0003	uM
2-cyclobutylsulfanyl-6-[3-(2,3-dihydro-1H-inden-2-ylamino)propanoyl]-3-phenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-one	1573540: Inhibition of recombinant human MGAT2 using 2-monooleoyl glycerol/[1-14C]-oleoyl CoA as substrate after 30 mins by liquid scintillation counting method	ic50	0.0004	uM
(2S)-N-(4-methoxyphenyl)-4-(4-methylphenyl)-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridine-5-carboxamide	1785300: Inhibition of human MGAT2 in mouse STC-1 cell based assay	ic50	0.0006	uM
2-cyclobutylsulfanyl-3-phenyl-6-[2-[5-[4-(trifluoromethyl)phenoxy]pentylamino]acetyl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-one	1573551: Inhibition of recombinant human MGAT2	ic50	0.0006	uM
N-[[(2S)-4-[5-(2-hydroxypropan-2-yl)-2-pyridinyl]-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-5-yl]methyl]-2-methylsulfonylacetamide	1573551: Inhibition of recombinant human MGAT2	ic50	0.0007	uM
N-[5-[(2,4-difluorophenyl)sulfamoyl]-1-(2-phenylethyl)-2,3-dihydroindol-7-yl]acetamide	1228343: In vitro inhibition of full length human MGAT2 transfected in FreeStyle293 cells assessed as dioleoylglycerol by RapidFire/MS assay	ic50	0.0010	uM
3-[(3S)-4’-(2-cyclopropyl-1,3-thiazol-5-yl)-6’-oxo-6-(4,4,4-trifluorobutoxy)spiro[1,2-dihydroindene-3,2’-1,3-dihydropyridine]-5’-yl]-4H-1,2,4-oxadiazol-5-one	1573551: Inhibition of recombinant human MGAT2	ic50	0.0010	uM
(2S)-4-[4-(difluoromethyl)phenyl]-2-[2-fluoro-4-(6,6,6-trifluorohexoxy)phenyl]-N-methylsulfonyl-6-oxo-2-(trifluoromethyl)-1,3-dihydropyridine-5-carboxamide	1573551: Inhibition of recombinant human MGAT2	ic50	0.0010	uM
2-cyclobutylsulfanyl-6-[3-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)propanoyl]-3-phenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-one	1573551: Inhibition of recombinant human MGAT2	ic50	0.0011	uM
N-[5-[(2,4-difluorophenyl)sulfamoyl]-1-[2-(4-fluorophenyl)ethyl]-2,3-dihydroindol-7-yl]acetamide	1228343: In vitro inhibition of full length human MGAT2 transfected in FreeStyle293 cells assessed as dioleoylglycerol by RapidFire/MS assay	ic50	0.0012	uM
2-[(1R)-1-(3,5-difluorophenyl)ethyl]-N-[3-(pyrrolidine-1-carbonyl)-1,2,4-oxadiazol-5-yl]-3,4-dihydro-1H-isoquinoline-7-sulfonamide	1573551: Inhibition of recombinant human MGAT2	ic50	0.0016	uM
N-(2,4-difluorophenyl)-3,3-diethyl-5-oxo-2,4-dihydro-1H-1,4-benzodiazepine-7-sulfonamide	745096: Inhibition of human recombinant MGAT2 expressed in insect cell membrane using 2-oleoyl-sn-glycerol and oleoyl coenzyme A as substrate after 40 mins by Ellmans assay based rapidfire LCMS analysis	ic50	0.0016	uM
(2S)-4-[1-(cyclopropylmethyl)pyrazol-3-yl]-2-[2-fluoro-4-(4,4,4-trifluorobutoxy)phenyl]-5-(2H-tetrazol-5-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	2015133: Inhibition of human MGAT2 using 2-oleoylglycerol and oleoyl-coenzyme A as substrate by LC-MS analysis	ic50	0.0019	uM
(2S)-4-(5-cyclopropyl-1,3-thiazol-2-yl)-2-[2-fluoro-4-(4,4,4-trifluorobutoxy)phenyl]-5-(5-oxo-1H-tetrazol-4-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	2015133: Inhibition of human MGAT2 using 2-oleoylglycerol and oleoyl-coenzyme A as substrate by LC-MS analysis	ic50	0.0019	uM
(2S)-N-cyclopentyl-4-(4-methylphenyl)-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridine-5-carboxamide	1785280: Inhibition of human recombinant MGAT2 expressed in Sf9 cell membrane using 2-monooleglycerol and [H3]-oleoyl-CoA as substrates incubated for 20 mins by scintillation proximity assay	ic50	0.0019	uM
N-[5-[(2,4-difluorophenyl)sulfamoyl]-1-(2-phenylethyl)indol-7-yl]acetamide	1228343: In vitro inhibition of full length human MGAT2 transfected in FreeStyle293 cells assessed as dioleoylglycerol by RapidFire/MS assay	ic50	0.0021	uM
N-[5-[(4-methoxyphenyl)sulfamoyl]-1-(2-phenylethyl)-2,3-dihydroindol-7-yl]acetamide	1228343: In vitro inhibition of full length human MGAT2 transfected in FreeStyle293 cells assessed as dioleoylglycerol by RapidFire/MS assay	ic50	0.0022	uM
benzyl 5-[(2,4-difluorophenyl)sulfamoyl]-7-(2-oxo-1,3-diazinan-1-yl)-2,3-dihydroindole-1-carboxylate	1228343: In vitro inhibition of full length human MGAT2 transfected in FreeStyle293 cells assessed as dioleoylglycerol by RapidFire/MS assay	ic50	0.0022	uM
(2S)-4-(5-cyclopropyl-1,3-thiazol-2-yl)-2-[2-fluoro-4-(4,4,4-trifluorobutoxy)phenyl]-5-(2H-tetrazol-5-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	2015133: Inhibition of human MGAT2 using 2-oleoylglycerol and oleoyl-coenzyme A as substrate by LC-MS analysis	ic50	0.0024	uM
5-[(2,4-difluorophenyl)sulfamoyl]-7-(2-oxoimidazolidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-2,3-dihydroindole-1-carboxamide	1228343: In vitro inhibition of full length human MGAT2 transfected in FreeStyle293 cells assessed as dioleoylglycerol by RapidFire/MS assay	ic50	0.0025	uM
4-(4-methoxyphenyl)-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridine-5-carbonitrile	1785280: Inhibition of human recombinant MGAT2 expressed in Sf9 cell membrane using 2-monooleglycerol and [H3]-oleoyl-CoA as substrates incubated for 20 mins by scintillation proximity assay	ic50	0.0025	uM
(2S)-4-(5-ethylthiophen-2-yl)-2-[2-fluoro-4-(4,4,4-trifluorobutoxy)phenyl]-5-(5-oxo-1H-tetrazol-4-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	2015133: Inhibition of human MGAT2 using 2-oleoylglycerol and oleoyl-coenzyme A as substrate by LC-MS analysis	ic50	0.0025	uM
(2S)-4-(4-methylphenyl)-5-(2H-tetrazol-5-yl)-2-(trifluoromethyl)-2-[4-(5,5,5-trifluoropentyl)phenyl]-1,3-dihydropyridin-6-one	1785280: Inhibition of human recombinant MGAT2 expressed in Sf9 cell membrane using 2-monooleglycerol and [H3]-oleoyl-CoA as substrates incubated for 20 mins by scintillation proximity assay	ic50	0.0026	uM
(2S)-2-[2-fluoro-4-(6,6,6-trifluorohexoxy)phenyl]-4-(4-methylphenyl)-5-(2H-tetrazol-5-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	1785280: Inhibition of human recombinant MGAT2 expressed in Sf9 cell membrane using 2-monooleglycerol and [H3]-oleoyl-CoA as substrates incubated for 20 mins by scintillation proximity assay	ic50	0.0026	uM
5-[(2,4-difluorophenyl)sulfamoyl]-7-(2-oxopyrrolidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-2,3-dihydroindole-1-carboxamide	1228343: In vitro inhibition of full length human MGAT2 transfected in FreeStyle293 cells assessed as dioleoylglycerol by RapidFire/MS assay	ic50	0.0031	uM
N-(2,4-difluorophenyl)-3,3-diethyl-2,5-dioxo-1,4-dihydro-1,4-benzodiazepine-7-sulfonamide	745096: Inhibition of human recombinant MGAT2 expressed in insect cell membrane using 2-oleoyl-sn-glycerol and oleoyl coenzyme A as substrate after 40 mins by Ellmans assay based rapidfire LCMS analysis	ic50	0.0032	uM
benzyl 5-[(2,4-difluorophenyl)sulfamoyl]-7-(2-oxoimidazolidin-1-yl)-2,3-dihydroindole-1-carboxylate	1228343: In vitro inhibition of full length human MGAT2 transfected in FreeStyle293 cells assessed as dioleoylglycerol by RapidFire/MS assay	ic50	0.0034	uM
N-(4-tert-butylphenyl)-5-[(2,4-difluorophenyl)sulfamoyl]-7-(2-oxopyrrolidin-1-yl)-2,3-dihydroindole-1-carboxamide	1228343: In vitro inhibition of full length human MGAT2 transfected in FreeStyle293 cells assessed as dioleoylglycerol by RapidFire/MS assay	ic50	0.0036	uM
N-[5-[(2,4-difluorophenyl)sulfamoyl]-1-(3-phenylpropyl)-2,3-dihydroindol-7-yl]acetamide	1228343: In vitro inhibition of full length human MGAT2 transfected in FreeStyle293 cells assessed as dioleoylglycerol by RapidFire/MS assay	ic50	0.0037	uM
N-[(1S)-1-[4-[[[(3S)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-3-yl]methylamino]methyl]phenyl]-2,2,2-trifluoroethyl]methanesulfonamide	1573548: Inhibition of recombinant human MGAT2 expressed in sf9 cells using 2-monooleoyl glycerol/[14C]-oleoyl CoA as substrate by microscintillation counting method	ic50	0.0038	uM
4-(4-methylphenyl)-6-oxo-N-phenyl-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridine-5-carboxamide	1785280: Inhibition of human recombinant MGAT2 expressed in Sf9 cell membrane using 2-monooleglycerol and [H3]-oleoyl-CoA as substrates incubated for 20 mins by scintillation proximity assay	ic50	0.0040	uM
ethyl 3-[4-[[3-(2-cyclohexylsulfanyl-4-oxo-3-phenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carbonyl)azetidin-1-yl]methyl]phenyl]propanoate	1573551: Inhibition of recombinant human MGAT2	ic50	0.0040	uM
3-ethyl-N-(4-methoxyphenyl)-3-methyl-2,5-dioxo-1,4-dihydro-1,4-benzodiazepine-7-sulfonamide	745096: Inhibition of human recombinant MGAT2 expressed in insect cell membrane using 2-oleoyl-sn-glycerol and oleoyl coenzyme A as substrate after 40 mins by Ellmans assay based rapidfire LCMS analysis	ic50	0.0040	uM
(2S)-4-(4-methylphenyl)-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-N-[4-(trifluoromethoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridine-5-carboxamide	1785280: Inhibition of human recombinant MGAT2 expressed in Sf9 cell membrane using 2-monooleglycerol and [H3]-oleoyl-CoA as substrates incubated for 20 mins by scintillation proximity assay	ic50	0.0042	uM
(2S)-4-(4-methylphenyl)-5-(tetrazol-1-yl)-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	2015133: Inhibition of human MGAT2 using 2-oleoylglycerol and oleoyl-coenzyme A as substrate by LC-MS analysis	ic50	0.0045	uM
(2S)-4-[1-(cyclopropylmethyl)pyrazol-3-yl]-2-[2-fluoro-4-(4,4,4-trifluorobutoxy)phenyl]-5-(5-oxo-1H-tetrazol-4-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	2015133: Inhibition of human MGAT2 using 2-oleoylglycerol and oleoyl-coenzyme A as substrate by LC-MS analysis	ic50	0.0046	uM
(2S)-2-[2-fluoro-4-(4,4,4-trifluorobutoxy)phenyl]-4-(4-methylphenyl)-5-(2H-tetrazol-5-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	1785280: Inhibition of human recombinant MGAT2 expressed in Sf9 cell membrane using 2-monooleglycerol and [H3]-oleoyl-CoA as substrates incubated for 20 mins by scintillation proximity assay	ic50	0.0050	uM
(2S)-N-(6-methoxy-3-pyridinyl)-4-(4-methylphenyl)-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridine-5-carboxamide	1785280: Inhibition of human recombinant MGAT2 expressed in Sf9 cell membrane using 2-monooleglycerol and [H3]-oleoyl-CoA as substrates incubated for 20 mins by scintillation proximity assay	ic50	0.0050	uM
(2S)-N-methyl-4-(4-methylphenyl)-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridine-5-carboxamide	1785280: Inhibition of human recombinant MGAT2 expressed in Sf9 cell membrane using 2-monooleglycerol and [H3]-oleoyl-CoA as substrates incubated for 20 mins by scintillation proximity assay	ic50	0.0052	uM
4-(4-ethoxyphenyl)-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridine-5-carbonitrile	1785280: Inhibition of human recombinant MGAT2 expressed in Sf9 cell membrane using 2-monooleglycerol and [H3]-oleoyl-CoA as substrates incubated for 20 mins by scintillation proximity assay	ic50	0.0053	uM
(2S)-2-(4-butylsulfanylphenyl)-4-(4-methylphenyl)-5-(2H-tetrazol-5-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	1785280: Inhibition of human recombinant MGAT2 expressed in Sf9 cell membrane using 2-monooleglycerol and [H3]-oleoyl-CoA as substrates incubated for 20 mins by scintillation proximity assay	ic50	0.0055	uM
(2S)-4-(4-methylphenyl)-5-(2H-tetrazol-5-yl)-2-[4-(6,6,6-trifluorohexoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	1785280: Inhibition of human recombinant MGAT2 expressed in Sf9 cell membrane using 2-monooleglycerol and [H3]-oleoyl-CoA as substrates incubated for 20 mins by scintillation proximity assay	ic50	0.0061	uM
(3S)-N-(2,4-difluorophenyl)-3-ethyl-3-methyl-2,5-dioxo-1,4-dihydro-1,4-benzodiazepine-7-sulfonamide	1573551: Inhibition of recombinant human MGAT2	ic50	0.0063	uM
N-(2,4-difluorophenyl)-7-(2-oxopyrrolidin-1-yl)-1-(2-phenylethyl)-2,3-dihydroindole-5-sulfonamide	1228343: In vitro inhibition of full length human MGAT2 transfected in FreeStyle293 cells assessed as dioleoylglycerol by RapidFire/MS assay	ic50	0.0067	uM
N-(4-methoxyphenyl)-4-(4-methylphenyl)-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridine-5-carboxamide	1785280: Inhibition of human recombinant MGAT2 expressed in Sf9 cell membrane using 2-monooleglycerol and [H3]-oleoyl-CoA as substrates incubated for 20 mins by scintillation proximity assay	ic50	0.0067	uM
(2S)-2-[2-fluoro-4-(4,4,4-trifluorobutoxy)phenyl]-4-(4-methylphenyl)-6-oxo-N-[4-(2H-tetrazol-5-yl)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridine-5-carboxamide	1573551: Inhibition of recombinant human MGAT2	ic50	0.0070	uM
(2S)-N-(6-methoxypyridazin-3-yl)-4-(4-methylphenyl)-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridine-5-carboxamide	1785280: Inhibition of human recombinant MGAT2 expressed in Sf9 cell membrane using 2-monooleglycerol and [H3]-oleoyl-CoA as substrates incubated for 20 mins by scintillation proximity assay	ic50	0.0071	uM
(2S)-4-(4-methylphenyl)-5-(2H-tetrazol-5-yl)-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	1785280: Inhibition of human recombinant MGAT2 expressed in Sf9 cell membrane using 2-monooleglycerol and [H3]-oleoyl-CoA as substrates incubated for 20 mins by scintillation proximity assay	ic50	0.0071	uM
4-(4-methylphenyl)-5-(2H-tetrazol-5-yl)-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-6-one	2015133: Inhibition of human MGAT2 using 2-oleoylglycerol and oleoyl-coenzyme A as substrate by LC-MS analysis	ic50	0.0071	uM

CTD chemical–gene interactions

42 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cadmium	increases expression, decreases expression, increases abundance	2
Nickel	increases expression	2
Valproic Acid	decreases methylation, increases expression	2
Cyclosporine	decreases expression, increases expression	2
Cadmium Chloride	decreases expression, increases abundance, increases expression	2
aristolochic acid I	increases expression	1
GSK-J4	decreases expression	1
7-(4,6-di-tert-butylpyrimidin-2-yl)-3-(4-trifluoromethoxyphenyl)-5,6,7,8-tetrahydro(1,2,4)triazolo(4,3-a)pyrazine	decreases activity	1
bisphenol F	affects cotreatment, increases expression	1
alpha phellandrene	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
isobutyl alcohol	affects cotreatment, decreases expression, increases abundance	1
2,3-dimethoxy-1,4-naphthoquinone	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
Lycopene	increases expression	1
Ethanol	affects cotreatment, decreases expression, increases abundance	1
Antimony	decreases expression	1
Antimony Potassium Tartrate	decreases expression	1
Atrazine	increases expression	1
Chromium	decreases expression	1
Cisplatin	decreases expression, decreases reaction	1
Dexamethasone	affects cotreatment, increases expression	1
Dimethylnitrosamine	decreases expression	1
Fluorouracil	affects response to substance	1
Gasoline	affects cotreatment, decreases expression, increases abundance	1
Indomethacin	affects cotreatment, increases expression	1
Mercury	decreases expression	1
Methyl Methanesulfonate	decreases expression	1

ChEMBL screening assays

32 unique, capped per target: 32 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2329320	Binding	Inhibition of human GNT2 GalNAc-transferase using GnMan3-octyl as substrate at 0.5 mM after 1 hr in presence of phosphatidylcholine	Selective inhibition of glycosyltransferases by bivalent imidazolium salts. — Bioorg Med Chem

Cellosaurus cell lines

8 cell lines: 6 spontaneously immortalized cell line, 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_C3MD	SfSWT-4	Spontaneously immortalized cell line	Female
CVCL_C3ME	SfSWT-5	Spontaneously immortalized cell line	Female
CVCL_C3MF	SfSWT-6	Spontaneously immortalized cell line	Female
CVCL_C3MG	SfSWT-7	Spontaneously immortalized cell line	Female
CVCL_SY25	HAP1 MGAT2 (-) 1	Cancer cell line	Male
CVCL_SY26	HAP1 MGAT2 (-) 2	Cancer cell line	Male
CVCL_Z366	SfSWT-1	Spontaneously immortalized cell line	Female
CVCL_Z367	SfSWT-3	Spontaneously immortalized cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.